药物重用趋势:在老年人群中推进心血管疾病管理
Murali Krishna Moka1, Melvin George1, Deepalaxmi Rathakrishnan1
1Department of Clinical Research, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India.
Current research in translational medicine
|January 23, 2025
概括
药物再利用在老年人中提供了有效的心血管疾病 (CVD) 管理. 本综述强调了老年心血管疾病患者有益的非心血管药物,并提出了有前途的治疗途径.
科学领域:
- 老年医学 老年医学
- 心血管药理学心血管药理学
- 药物发现 药物发现 药物发现
背景情况:
- 心血管疾病 (CVD) 由于与年龄相关的生理变化和累积风险因素,显著影响老年人群.
- 中年 (40-65岁) 是心血管疾病发展的关键时期,受肥胖和压力等生活方式因素的影响.
- 在65岁及以上的人群中,心脏病发病率上升,需要有效的管理策略.
研究的目的:
- 审查药物重定向在老年人群中治疗心血管疾病 (CVD) 的潜力.
- 确定可用于老年人心血管益处的非心血管药物.
- 评估老年心血管疾病管理的特定药物的治疗效用和局限性.
主要方法:
- 系统审查现有的关于药物重新利用老年人心血管健康的文献.
- 分析非心血管药物对老年人潜在的心血管益处的分析.
- 评估药物的有效性,安全性和适合老年人重新使用的适用性.
主要成果:
- 一些非心血管性药物,包括anakinra,probenecid,N-acetylcysteine,quercetin,resveratrol,rapamycin,colchicine,bisphosphonates,hydroxychloroquine,SGLT-2抑制剂,GLP-1受体激动剂和西尔德纳菲尔,显示出在老年心血管疾病中重新定位的希望.
- 诸如canakinumab,甲铁酸,ivermectin,erythromycin,capecitabine,carglumic acid,chloroquine和furosemide等药物存在局限性,并且需要对此应用进行仔细考虑.
- 药物重新定位成为一种具有成本效益和高效的策略,以提高老年人心血管疾病治疗的疗效.
结论:
- 药物重新定位是改善老年患者心血管疾病管理的可行和有前途的策略.
- 建议使用特定的非心血管药物,以实现老年人的心血管益处.
- 进一步探索替代治疗策略,包括药物重定向,对于提高老年人群的治疗结果至关重要.
相关概念视频
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:21Factors Affecting Drug Response: Overview
1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
449
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
449
01:26Heart Failure Drugs: Inotropic Agents
510
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
510